BRCA2 Antikörper (AA 2990-3232)
-
- Target Alle BRCA2 Antikörper anzeigen
- BRCA2 (Breast Cancer 2, Early Onset (BRCA2))
-
Bindungsspezifität
- AA 2990-3232
-
Reaktivität
- Maus
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser BRCA2 Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB), Immunohistochemistry (IHC), Immunoprecipitation (IP), Immunofluorescence (fixed cells) (IF/ICC)
- Aufreinigung
- Antigen-specific affinity chromatography followed by Protein A affinity chromatography
- Immunogen
- BRCA2 (Glu2990-Ala3232)
- Top Product
- Discover our top product BRCA2 Primärantikörper
-
anti-Breast Cancer 2, Early Onset (BRCA2) (AA 21-130) antibody
BRCA2 Reaktivität: Human WB, ELISA, IF (cc), IF (p), IHC (p), IHC (fro) Wirt: Kaninchen Polyclonal unconjugated
anti-Breast Cancer 2, Early Onset (BRCA2) antibodyBRCA2 Reaktivität: Human, Ratte WB, IHC, IF Wirt: Kaninchen Polyclonal unconjugated
anti-Breast Cancer 2, Early Onset (BRCA2) (AA 2990-3232) antibodyBRCA2 Reaktivität: Maus WB, IHC, IP, ICC Wirt: Kaninchen Polyclonal unconjugated
anti-Breast Cancer 2, Early Onset (BRCA2) (AA 3319-3418) antibodyBRCA2 Reaktivität: Human WB, ELISA Wirt: Maus Monoclonal 3D12 unconjugated
anti-Breast Cancer 2, Early Onset (BRCA2) (AA 1-300) antibodyBRCA2 Reaktivität: Human WB, IF Wirt: Kaninchen Polyclonal unconjugated
anti-Breast Cancer 2, Early Onset (BRCA2) (AA 2913-3151) antibodyBRCA2 Reaktivität: Ratte WB, IHC, ICC Wirt: Kaninchen Polyclonal unconjugated
anti-Breast Cancer 2, Early Onset (BRCA2) (AA 2308-2537) antibodyBRCA2 Reaktivität: Human WB, IHC, IP, ICC Wirt: Kaninchen Polyclonal unconjugated
anti-Breast Cancer 2, Early Onset (BRCA2) (AA 2737-2874) antibodyBRCA2 Reaktivität: Zebrafisch (Danio rerio) WB, ELISA Wirt: Kaninchen Polyclonal unconjugated
anti-Breast Cancer 2, Early Onset (BRCA2) (pSer3291) antibodyBRCA2 Reaktivität: Human WB, ELISA Wirt: Kaninchen Polyclonal unconjugated
anti-Breast Cancer 2, Early Onset (BRCA2) (AA 251-495) antibodyBRCA2 Reaktivität: Human WB Wirt: Maus Monoclonal 1643CT739-91-87 unconjugated
-
- Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 500 μg/mL
- Buffer
- PBS, pH 7.4, containing 0.02 % Sodium azide, 50 % glycerol.
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- 4 °C,-20 °C
- Informationen zur Lagerung
- Store at 4 °C for frequent use. Aliquot and store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
-
- Target
- BRCA2 (Breast Cancer 2, Early Onset (BRCA2))
- Andere Bezeichnung
- Breast Cancer Susceptibility Protein 2 (BRCA2 Produkte)
- Synonyme
- BRCC2 antikoerper, BROVCA2 antikoerper, FACD antikoerper, FAD antikoerper, FAD1 antikoerper, FANCB antikoerper, FANCD antikoerper, FANCD1 antikoerper, GLM3 antikoerper, PNCA2 antikoerper, 30169 antikoerper, BcDNA:SD25109 antikoerper, CG13583 antikoerper, CG13584 antikoerper, CG30169 antikoerper, Dmel\\CG30169 antikoerper, brca2 antikoerper, dmbrca2 antikoerper, fancd1 antikoerper, BRCA2 antikoerper, brcc2 antikoerper, brovca2 antikoerper, facd antikoerper, fad antikoerper, fad1 antikoerper, fancb antikoerper, AI256696 antikoerper, AW045498 antikoerper, Fancd1 antikoerper, RAB163 antikoerper, BRCA2, DNA repair associated antikoerper, Breast cancer 2, early onset homolog antikoerper, breast cancer 2, early onset antikoerper, BRCA2 antikoerper, Brca2 antikoerper, brca2 antikoerper, LOC584780 antikoerper
- UniProt
- P97929
- Pathways
- DNA Reparatur, M Phase, Maintenance of Protein Location
-
